Follow us on LinkedIn - https://www.linkedin.com/company/fatty-liver-alliance/
Check out some of the latest news around the world.
December 2, 2021
IMPORTANT LIVER HEALTH NEWS: European panel of experts recommend digital and social media ban on marketing of all alcohol and ultra-processed, high-fat, and high-sugar foods targeted to children.
EASL-Lancet Liver Commission Recommendations:
1) Implementation of standardized and simplified liver blood tests for earlier detection and prompt care.
2) Utilization of opportunities created by the hepatitis B and C drugs as well as hepatitis B and A vaccines to achieve viral hepatitis elimination in Europe.
3) Increase awareness and provide financial incentives for primary care peers and professionals.
4) Non-viral liver diseases must be classified along with other non-communicable diseases (NCDs) to engage appropriate care models.
5) All forms and sources of stigma towards people at risk of or with liver disease must be opposed - relevant changes to the medical nomenclature should come first.
6) Public disclosure of prices for antiviral drugs throughout Europe would reinforce the WHO / World Health Assembly resolution to improve fairness of market prices
7) European governments must introduce uniform policies to reduce the harmful use of alcohol
8) A complete social and digital media ban on the marketing of alcohol and ultraprocessed, high-fat and high-sugar foods targeted to children.
9) Promote industry-led food reformulation and minimization of social inequities by subsidizing healthy foods.
10) EU and European governments should prioritize the harmonization of critical forms of public health interventions and health-related policies across Europe.
July 26, 2021,
Two most commonly used non-invasive 'fibrosis risk' blood tests may show different results, leading to different courses of action.
Conclusion: "In a primary care NAFLD cohort, many patients had elevated FIB-4 and NFS risk scores and these risk categories were often in disagreement. The choice between FIB-4 and NFS for fibrosis risk assessment can impact clinical decision-making and may contribute to disparities of care."
July 23, 2021,
Journal of Hepatology
A recent Texas study with 664 inclusion qualifying participants (a cohort of asymptomatic middle-aged US adults), highlights a higher prevalence of NAFLD and NASH than previously thought. Findings published in the Journal of Hepatology were: "Based on liver histology data, NASH was diagnosed in 14% of the entire cohort and 37% of those with NAFLD." "NASH was more common in Hispanics and those with obesity or type 2 diabetes."
"Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort".
Authors: Stephen A. Harrison, Samer Gawrieh, Katharine Roberts, Céline Fournier, Angelo H. Paredes and Naim Alkhouri.
July 17, 2021,
hep - Science News
"Mice fed a Western diet high in calories and fat develop non-alcoholic steatohepatitis (NASH) and progress to developing liver cancer as well as kidney and heart disease. The findings, published in Cellular and Molecular Gastroenterology and Hepatology, also showed that switching the Western diet for one with appropriate amounts of macronutrients reversed the development of NASH and, subsequently, prevented cancer and related death."
June 14, 2021
KHSB Kansas City
News highlights NASH as a silent disease.
May 14, 2021
Gastroenterology and Endocopy News
“When you look at patients’ baseline scores, one thing is pretty clear,” Younossi told Gastroenterology & Endoscopy News. “While most of us thought NASH is an asymptomatic disease, that is not true.”
"In fact, Younossi’s team found, approximately 40% of NASH patients—even those in the early stages of disease—reported significant fatigue. “Furthermore, 20% to 25% of NASH patients have pruritus, which is not something we’ve thought about in NASH. Finally, we found that between 18% and 20% have some form of abdominal discomfort that they complain about,” he said."
The link to the original story is:
May 13, 2021
This study looked at the prevalence and risk factors for MAFLD (metabolic associated fatty liver disease in a population of Chinese patients who were diagnosed with nonalcoholic fatty liver disease.
They examined 139,700 patients and found a MAFLD prevalence rate of 26.1% and that those who were overweight, as defined by their BMI had a MAFLD prevalence rate of 27.4% and if defined as obese, 59.8%. Many other risk factors were also studied and results shared in this study.
The paper does make the claim that the term NAFLD has been replaced with MAFLD. "Metabolic associated fatty liver disease (MAFLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is a new definition of liver disease associated with known metabolic dysfunction and is the most common chronic liver disease worldwide."
The link to the original paper is:
May 11, 2021
“It is estimated that 30 to 40 percent of adults in the United States have fatty liver disease, which is between one-third and one-half of all the people you know! Given how common fatty liver is, everyone needs to understand what it means, how to treat it, and what you can do if your doctor ever looks at your blood test and tells you that you have what's called Nonalcoholic Fatty Liver Disease, or NAFLD."
May 6, 2021
Cleaveland Clinic - health essentials
“In people who already have nonalcoholic fatty liver disease, regular coffee drinking lowers the odds of developing cirrhosis. And among people who have cirrhosis, those who drink more coffee are less likely to die from the disease."
March 30, 2021
News Medical Life Sciences
“NAFLD affects more than 1-in-10 children in the U.S. and now is the nation's most common chronic liver disease within this population. The disease can lead to nonalcoholic steatohepatitis (NASH), a chronic condition that can lead to serious illness, liver transplants, and death. Risk factors include obesity and family history.” "In this review, researchers focused on studies that linked excessive fructose intake to children with NAFLD, interventions that restricted fructose, and identification of related metabolic biomarkers."
March 25, 2021
“The data presented at ENDO 2021 highlights tesamorelin’s unique mechanism of action that addresses the underlying cause of liver disease and further supports the Phase 3 development of this novel medicine for the potential treatment of NASH,” said Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer at Theratechnologies.”
March 19, 2021
“Gilead is pleased to expand our collaboration with Novo Nordisk and advance understanding of the potential for combination approaches in treating people living with cirrhosis due to NASH,” said Mark Genovese, MD, Senior Vice President, Inflammation Clinical Development at Gilead Sciences. “This study is the latest example of our persistent focus on driving innovation to improve the lives of people living with liver diseases and fibrosis.”